

# Renovalase<sup>TM</sup> Vaginal atrophy laser treatment

- solution for symptoms of vaginal atrophy
- photo-thermal treatment of the vaginal canal
- functional restoration of vaginal mucosa
- safe treatment without long-term hormonal therapy
- minimally invasive
- no anesthesia needed
- walk-in/walk-out procedure





The drop in estrogen hormone levels after menopause (natural or induced) causes persistent and troublesome vaginal atrophy symptoms such as dryness, itching, vaginal irritation and pain during intercourse (dyspareunia). These symptoms can have an adverse impact on a sexual life which is already partially compromised by the loss of libido due to hormonal deficiency.

## What is RenovaLase™?

RenovaLase™ is an innovative and unique, non-invasive 2940 nm Er:YAG laser therapy for the symptoms of vaginal atrophy. It is based on non-ablative photothermal treatment of the vaginal canal.

Preliminary clinical studies show that it is an efficient, easy-to-use, quick and safe procedure, without the need for long-term hormone consumption.

## Promising clinical Results

The latest scientific results presented by LA&HA specialist Dr. Adrian Gaspar clearly show a noticeable improvement in the symptoms of vaginal atrophy.

Results show favourable changes in the tropism of the vaginal mucosa, with increases in collagen and vascularization as well as in the glycogen level and the epithelial thickness.


There was no ablation of the tissue or thermal damage, so no complications were connected.

The positive effects were long lasting as results were sustained at a 6-month follow-up. With no need for long-term hormonal treatment, RenovaLase™ is also appropriate for patients with hormone-dependent cancer (such as melanomas, endometrial cancer, breast cancer) or with a family background of such cancers.

#### How does RenovaLase™ work?

The RenovaLase treatment is based on laser-induced thermal effects in the vaginal tissue, stimulating collagenesis, cellularity of the extracellular matrix, papillomatosis and angiogenesis, without thermal or ablative damage.

The final result is increased epithelial thickness as well as vascularization of the lamina propria, along with




Atrophic vaginal mucosa

a reduction of symptoms such as dryness, itching, irritation and dyspareunia.

#### Getting started with RenovaLase™

After clinical investigation and approval, training in RenovaLase™ will be provided through the Laser and Health Academy (www. laserandhealth.com) as a standalone training workshop under the guidance of experts in medical laser technology. The extensive workshop, where participants engage in live demonstrations and gain an in-depth understanding of laser physics and laser-tissue interaction, will provide the needed insight into the fundamentals of noninvasive gynecological treatments and other procedures that can be performed with this special Er:YAG laser system.



Vaginal mucosa after Renova Lase treatment, with increases in vascularization, collagen, the glycogen level and epithelial thickness.



Adrian Gaspar, MD; Mendoza University, Argentina

"I'm especially thrilled with the positive results we've had when treating vaginal atrophy. The use of the FotonaSmooth<sup>TM</sup> laser in this very common pathology has set a new standard of treatment for my practice. We are able to move away from long-term hormone replacement therapies that have received negative media attention and created concern in our patients, and toward laser light treatments that have the patient symptom-free for many months with no adverse complications."

All Fotona medical lasers are CE marked and approved to be sold in the EU. RenovaLase treatment is not yet CE approved or cleared by the US FDA. RenovaLase is now under clinical investigation for the treatment of symptoms of vaginal atrophy. For countries where specific national approvals or clearances are required, some of the products and/or applications may not yet have been approved. Please check with Fotona, your local Fotona distributor or your national regulatory body whether a specific product or application has been approved to be marketed and sold in your country.